{"entity":{"id":"azd7789","kind":"drug","name":"AZD7789","aka":[],"tldr":"AZD7789 is an experimental bispecific antibody from AstraZeneca in phase 2 trials for non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer, aimed at PD-1 and TIM-3.","summary":"AZD7789 is a bispecific antibody developed by AstraZeneca. Its targets are PD-1 and TIM-3 (the sponsor names PD-1 x TIM-3). The sponsor states: An anti-PD-1 and anti-TIM-3 bispecific antibody that simultaneously engages both immune checkpoints to enhance anti-tumour immunity. ClinicalTrials.gov describes the intervention as: anti-PD-1 and anti-TIM-3 bispecific antibody. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer. The largest, NCT04931654, plans to enrol 136 participants (actual) with primary completion was scheduled for 2024-12-04 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of AZD7789","url":"https://clinicaltrials.gov/search?intr=AZD7789"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","gastric"],"sections":[],"technologies":[],"targets":["pd1","tim3"],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04931654"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"bispecific antibody","mechanism":"An anti-PD-1 and anti-TIM-3 bispecific antibody that simultaneously engages both immune checkpoints to enhance anti-tumour immunity.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/azd7789/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"gastric-pdl1-high","kind":"cancer","name":"PD-L1-high gastric cancer","route":"/cancers/gastric-pdl1-high/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"tim3","kind":"target","name":"TIM-3","route":"/targets/tim3/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"trial":[{"id":"nct04931654","kind":"trial","name":"A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer","route":"/trials/nct04931654/"}]}}